Itinai.com light and shadow chase in a bright clinical trial 94e57646 2deb 4898 b35d 841dc91eb7a5 1
Itinai.com light and shadow chase in a bright clinical trial 94e57646 2deb 4898 b35d 841dc91eb7a5 1

Assessment of MMP levels in reversible and irreversible pulpitis and a randomized controlled trial comparing clinical success of two different calcium-silicate cements in pulpotomy treatment of primary molars with an 18-month follow-up

Assessment of MMP Levels and Clinical Success in Pulpitis and Pulpotomy Treatment

Background

Matrix metalloproteinases (MMPs) are crucial enzymes in dental pulp tissue function. However, their role in primary teeth remains limited. Further studies are needed to understand their contributions to pulpal defense in primary teeth. Additionally, the effectiveness of Biodentine in treating primary teeth requires further exploration.

Aim

The study aims to compare MMP-2, MMP-8, and MMP-9 levels in reversible and irreversible pulpitis. It also seeks to assess the success of Mineral Trioxide Aggregate (MTA) and Biodentine in pulpotomy treatments for primary molars.

Design

63 primary molars were included in a randomized trial, with subgroups based on pulpitis diagnosis. MMP levels were evaluated for all samples, and pulpotomy treatments were performed using MTA and Biodentine in respective subgroups. Clinical and radiographic evaluations were conducted over an 18-month follow-up period.

Results

MMP-2 and MMP-9 levels were significantly elevated in irreversible pulpitis cases, suggesting a potential correlation with pulpal inflammation severity. Clinical success rates of pulpotomies with MTA and Biodentine were similar for reversible pulpitis cases.

Conclusions

The study suggests that MMP-2 and MMP-9 levels can serve as biomarkers for assessing pulpal inflammation in primary teeth. Moreover, Biodentine demonstrates promising clinical success in pulpotomy procedures, supporting its efficacy as an alternative to MTA.

Clinical Trial Registration

The study protocol has been registered with an ID: NCT05145686. Registration Date: 9th November 2021.

PMID:39215293 | PMC:PMC11365239 | DOI:10.1186/s12903-024-04795-5

Clinical trials play a crucial role in advancing medical treatments. Our AI-driven platform, DocSym, consolidates clinical standards and research for easy clinician access. Additionally, our mobile apps support scheduling, treatment monitoring, and telemedicine, streamlining clinic operations and extending patient care digitally.

AI integration in clinics can enhance workflows and improve patient outcomes, reducing paperwork. Visit aidevmd.com to learn more about how we can help.

AI-Powered Health Tools

Interactive AI Tools to Help You Understand Your Health

Solutions for Smart Healthcare

Clinical Research